Pharscin Pharmaceutical Gets Nod to Re-Register API and Drugs

MT Newswires Live10-22

Chongqing Pharscin Pharmaceutical (SHE:002907) obtained approval from the drug administration of China's Chongqing municipality to re-register an active pharmaceutical ingredient or API and five drugs with their specific measurements, according to a Monday filing on the Shenzhen Stock Exchange.

The pharmaceutical company will re-register the API, sodium ferulate, and the drugs, inosine tablets, metronidazole tablets, 20 milligrams and 50mg of batilol tablets, cimetidine capsules, and 0.1 grams, 0.3g and 50mg of isoniazid tablets.

The renewed certificates for all products are valid until Oct. 16, 2029, the filing said.

The company's shares closed 1% higher.

Price (RMB): ¥13.62, Change: ¥+0.17, Percent Change: +1.26%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477383266?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477383266","market":"nz","top_or_hot":-1,"title":"Pharscin Pharmaceutical Gets Nod to Re-Register API and Drugs","media":"MT Newswires Live","content":"<html><body><p> Chongqing Pharscin Pharmaceutical (SHE:002907) obtained approval from the drug administration of China's Chongqing municipality to re-register an active pharmaceutical ingredient or API and five drugs with their specific measurements, according to a Monday filing on the Shenzhen Stock Exchange.</p><p>The pharmaceutical company will re-register the API, sodium ferulate, and the drugs, inosine tablets, metronidazole tablets, 20 milligrams and 50mg of batilol tablets, cimetidine capsules, and 0.1 grams, 0.3g and 50mg of isoniazid tablets.</p><p>The renewed certificates for all products are valid until Oct. 16, 2029, the filing said.</p><p>The company's shares closed 1% higher.</p><p>Price (RMB): ¥13.62, Change: ¥+0.17, Percent Change: +1.26%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharscin Pharmaceutical Gets Nod to Re-Register API and Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharscin Pharmaceutical Gets Nod to Re-Register API and Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 17:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chongqing Pharscin Pharmaceutical (SHE:002907) obtained approval from the drug administration of China's Chongqing municipality to re-register an active pharmaceutical ingredient or API and five drugs...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTX.SI","symbol_name":"迈怡汇有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477383266","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477383266","pubTimestamp":1729590593,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chongqing Pharscin Pharmaceutical  obtained approval from the drug administration of China's Chongqing municipality to re-register an active pharmaceutical ingredient or API and five drugs with their specific measurements, according to a Monday filing on the Shenzhen Stock Exchange.The pharmaceutical company will re-register the API, sodium ferulate, and the drugs, inosine tablets, metronidazole tablets, 20 milligrams and 50mg of batilol tablets, cimetidine capsules, and 0.1 grams, 0.3g and 50mg of isoniazid tablets.The renewed certificates for all products are valid until Oct. 16, 2029, the filing said.The company's shares closed 1% higher.Price : 13.62, Change: +0.17, Percent Change: +1.26%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OTX.SI":"迈怡汇有限公司","BK6520":"工商业服务概念","002907":"华森制药","BK0239":"医药制造","BK6100":"保健护理服务"},"translate_title":"Pharscin Pharmaceutical获得重新注册API和药物的批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTX.SI":1,"002907":0.9},"content_text":"Chongqing Pharscin Pharmaceutical (SHE:002907) obtained approval from the drug administration of China's Chongqing municipality to re-register an active pharmaceutical ingredient or API and five drugs with their specific measurements, according to a Monday filing on the Shenzhen Stock Exchange.The pharmaceutical company will re-register the API, sodium ferulate, and the drugs, inosine tablets, metronidazole tablets, 20 milligrams and 50mg of batilol tablets, cimetidine capsules, and 0.1 grams, 0.3g and 50mg of isoniazid tablets.The renewed certificates for all products are valid until Oct. 16, 2029, the filing said.The company's shares closed 1% higher.Price (RMB): ¥13.62, Change: ¥+0.17, Percent Change: +1.26%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477383266"}